Webinars

May 2024

The aim of the webinar is to increase awareness of the challenges associated with generating PRO data and its value to different stakeholders and generate discussion to inform potential solutions to these challenges. Finally, the webinar will provide information about the content of the SISAQOL-IMI recommendations and how they can be used.

Sponsored by Inovalon

Apr 2024

Join Inovalon’s experts as they discuss the power of combining RCT with real-world data, through innovative data-linking techniques, to transform understanding of the patient journey to uncover invaluable insights into clinical and economic outcomes in the real-world.

Feb 2023

The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.

Jan 2023

An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.

Apr 2024

In this webinar, experts will characterize financial toxicity from the patient perspective, suggest potential frameworks for incorporation of financial toxicity into economic evaluation, and discuss areas where further research is necessary.

Sponsored by FIFARMA

Aug 2023

Value-Based Procurement (VBP) is a critical element of a value-based healthcare system, offering a transformative purchase approach that addresses underlying barriers to access to innovative treatments. Unlike the traditional procurement methods that focus primarily on cost containment, VBP considers multiple factors, including the unique circumstances of each country, such as local disease burden, health priorities, infrastructure, supply chain, ability to pay for healthcare, and budget processes.

Jul 2023

This webinar aims to provide insights into the economic evaluation of digital health technology, which presents unique challenges compared to pharmaceuticals, healthcare services, and medical devices. In this webinar, you will learn about the current role of health economics and outcomes research in assessing the value of digital health technologies, as well as the impact of digital health interventions in today’s healthcare systems.

Apr 2023

In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)

Sponsored by PINC AI™ Applied Sciences, a Division of Premier

Apr 2024

In this session, we'll discuss leveraging RWE to enhance diversity within clinical trials and expedite the translation of research findings into real-world clinical practice. Our expert panel will illuminate how RWE can address existing disparities in clinical trial participation, amplify the voices of underrepresented communities, and ultimately lead to more effective and equitable healthcare interventions.

Dec 2023

This webinar will provide a brief background on tokenization and its benefits. It will focus on end-to-end considerations for tokenizing data of clinical trial participants and designing fit for purpose studies based on linked real-world datasets.

Sep 2023

This webinar will cover the opportunities and challenges of collecting real-world data (RWD) and generating real-world evidence (RWE) for making better decisions in healthcare, specifically in Health Technology Assessment (HTA).

Jul 2023

In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.

Sep 2023

Stated preference surveys often involve communicating large volumes of complex and/or unfamiliar medical information to provide context for respondents. This webinar examines innovative uses of technology to advance discrete choice experiment (DCE) research within health preference research. They will explore the different technologies that can be integrated into preference surveys illustrating how technology can better inform and potentially engage respondents.

Jul 2023

With the public comment period open until July 2023, this webinar will also present ISPOR members with the opportunity to ask questions and provide comments that will help inform ISPOR’s response on the draft guidance 4 document.

Sponsored by PINC AI™ Applied Sciences, a Division of Premier

Jun 2023

Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.

Mar 2023

In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.

Jun 2024

Hear from ISPOR’s Chief Science Officers, who will begin with the methods underlying the report, and then will discuss each of the Top 10 topics, the HEOR considerations related to each one, and how ISPOR members are engaged in them, and will conclude with a question and answer period.

May 2024

The webinar will begin with an introduction of the participants of the study to the ISPOR Rare Disease (RD) SIG, followed by an overview of the study objectives, its methodology and findings. The novel study explored the burden of different RDs across a range of countries, including low-and-middle-income countries (LMICs). The diseases and countries were chosen to allow for a diverse and relevant representation of RD burden globally, aiming to capture cross-disease and cross-country unmet needs, and consequent areas for policy intervention.

Oct 2023

The aim of this webinar is to discuss real-life examples on how biosimilar adoption has positively impacted care and patient access to biological therapies, focusing on testimonies from patient, policy, and healthcare professional representatives. Speakers are invited to converse on what the tangible benefits are that biosimilars have delivered for patients, and how biosimilar availability has supported access to care and the implementation of optimized disease management initiatives.

Sponsored by FIFARMA

Jul 2023

This webinar will inaugurate the third edition of the series of webinars sponsored by FIFARMA on Value and Access to Innovation, and will be focused on exploring the relationship between health and the economy and how to ensure the long term healthcare system sustainability.

Sponsored by Novo Nordisk

May 2024

Obesity is a health priority for many governments because of its impact on population health and its economic consequences. We aimed to measure the wider effects of obesity in Japan and Canada by using a government perspective framework that accounts for lost tax revenues and higher government spending on social benefit programs.

Jun 2023

This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.

Apr 2023

The webinar will provide an overview of past and current efforts in health equity, its role in health outcomes research, and its future implications in the field.

Sponsored by FIFARMA

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".

Sponsored by GSK

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.

Sponsored by GSK

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Sponsored by Biogen

Jun 2021

A one-hour educational webinar on the implications of matched adjusted indirect treatment comparisons in rare disease, using SMA as an example. Webinar will provide both statistical and clinical perspective.

Sponsored by Biogen

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.